retatrutide ada 2025 results More data on dropped today at the conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase ADA 2026 Obesity Drug Updates:
Description
In its phase 3 TRIUMPH-4 study, the company reported that its new triple-agonist injection, retatrutide, produced an average 28.7% reduction in body weight over 68 weeksa result that surpasses even the blockbuster Zepbound
Get started with Klinic today
GLP-1 Daily Support Fiber blends soluble and insoluble fibers with postbiotics to support GLP-1 activation, promote satiety, and enhance digestive regularity
A third target is intestinal microbiomes and metabolic endotoxemia
Vitamin B6 25.5mg (as pyridoxal 5-phosphate / P5P) active form supporting energy production and metabolism
Vitamin D3 works with HMB to support muscle mass and strength.*6-11,13,25,27,28
